Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis
dc.contributor.author | Dodd, J. | |
dc.contributor.author | Crowther, C. | |
dc.contributor.author | Cincotta, R. | |
dc.contributor.author | Flenady, V. | |
dc.contributor.author | Robinson, J. | |
dc.date.issued | 2005 | |
dc.description | The definitive version is available at www.blackwell-synergy.com | |
dc.description.abstract | <h4>Aim</h4>The aim of this study is to assess the role of progesterone in preterm birth prevention.<h4>Methods</h4>A MEDLINE search (from 1966 to the present; date of last search January 2005) was performed - using the key words progesterone, pregnancy, preterm birth, preterm labor, and randomized, controlled trial - in order to identify randomized, controlled trials in which progesterone (either intramuscular or vaginal administration) was compared with placebo or no treatment. Data were extracted and a meta-analysis was performed.<h4>Results</h4>Seven randomized, controlled trials were identified. Women who received progesterone were statistically significantly less likely to give birth before 37 weeks (seven studies, 1020 women, RR = 0.58, 95% CI = 0.48-0.70), to have an infant with birth weight of < or =2.5 kg (six studies, 872 infants, RR = 0.62, 95% CI = 0.49-0.78), or to have an infant diagnosed with intraventricular hemorrhage (one study, 458 infants, RR = 0.25, 95% CI = 0.08-0.82).<h4>Conclusions</h4>For progesterone supplementation to be advocated for women at the risk of preterm birth, the prolongation of gestation demonstrated in this meta-analysis must translate into improved infant outcomes, including a reduction in mortality. There is currently insufficient information to allow recommendations regarding the optimal dose, route, and timing of administration of progesterone supplementation. | |
dc.description.statementofresponsibility | Jodie M. Dodd, Caroline A. Crowther, Robert Cincotta, Vicki Flenady, Jeffrey S. Robinson | |
dc.identifier.citation | Acta Obstetricia et Gynecologica Scandinavica, 2005; 84(6):526-533 | |
dc.identifier.doi | 10.1111/j.0001-6349.2005.00835.x | |
dc.identifier.issn | 0001-6349 | |
dc.identifier.issn | 1600-0412 | |
dc.identifier.orcid | Dodd, J. [0000-0002-6363-4874] | |
dc.identifier.orcid | Crowther, C. [0000-0002-9079-4451] | |
dc.identifier.orcid | Robinson, J. [0000-0002-4515-6039] | |
dc.identifier.uri | http://hdl.handle.net/2440/17251 | |
dc.language.iso | en | |
dc.publisher | Munksgaard Int Publ Ltd | |
dc.source.uri | http://www.blackwell-synergy.com/doi/abs/10.1111/j.0001-6349.2005.00835.x | |
dc.subject | Humans | |
dc.subject | Birth Weight | |
dc.subject | Progesterone | |
dc.subject | Tocolytic Agents | |
dc.subject | Administration, Intravaginal | |
dc.subject | Gestational Age | |
dc.subject | Pregnancy | |
dc.subject | Infant, Newborn | |
dc.subject | Female | |
dc.subject | Obstetric Labor, Premature | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.title | Progesterone supplementation for preventing preterm birth: a systematic review and meta-analysis | |
dc.type | Journal article | |
pubs.publication-status | Published |